FY2026 EPS Estimates for Beigene Lowered by Leerink Partnrs

Beigene, Ltd. (NASDAQ:ONC) – Research analysts at Leerink Partnrs lowered their FY2026 earnings per share (EPS) estimates for Beigene in a research report issued to clients and investors on Thursday, February 27th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn $7.06 per share for the year, down from their prior forecast of $7.33. The consensus estimate for Beigene’s current full-year earnings is ($5.82) per share.

Beigene (NASDAQ:ONC) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.55). The business had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%.

ONC has been the subject of several other reports. Macquarie raised their price target on Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research report on Friday. Bank of America upgraded Beigene from a “neutral” rating to a “buy” rating and lifted their target price for the company from $207.00 to $320.00 in a report on Monday.

Beigene Stock Performance

ONC opened at $245.53 on Monday. Beigene has a 52 week low of $126.97 and a 52 week high of $287.88. The firm has a market cap of $24.03 billion, a PE ratio of -29.80, a PEG ratio of 7.73 and a beta of 0.63. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05.

Insider Transactions at Beigene

In other news, SVP Chan Henry Lee sold 1,202 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $258.04, for a total transaction of $310,164.08. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Bros. Advisors Lp Baker sold 732,827 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $260.00, for a total value of $190,535,020.00. Following the sale, the director now directly owns 730,642 shares in the company, valued at $189,966,920. This trade represents a 50.07 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 790,950 shares of company stock worth $204,616,547. Corporate insiders own 7.43% of the company’s stock.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.